Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03158688
Registration number
NCT03158688
Ethics application status
Date submitted
9/05/2017
Date registered
18/05/2017
Titles & IDs
Public title
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Query!
Scientific title
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Query!
Secondary ID [1]
0
0
2016-003554-33
Query!
Secondary ID [2]
0
0
20160275
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CANDOR
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsed Multiple Myeloma
0
0
Query!
Refractory Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Daratumumab
Treatment: Drugs - Carfilzomib
Active comparator: Kd - Carfilzomib and Dexamethasone - Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.
Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.
Experimental: KdD - Carfilzomib, Dexamethasone and Daratumumab - Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.
Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.
Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only.
Treatment: Drugs: Dexamethasone
Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
Treatment: Drugs: Daratumumab
Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
Treatment: Drugs: Carfilzomib
Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.
Dose could be modified based on a \>20% change in body weight or toxicity.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)
Query!
Assessment method [1]
0
0
Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). The duration of PFS was right censored for participants who met any of the following conditions: 1. no baseline/post-baseline disease assessments; 2. started a new anti myeloma therapy before documentation of progressive disease or death; 3. progressive disease or death immediately after more than 70 days without disease assessment visit or; 4. alive without documentation of disease progression before the analysis trigger date (PA DCO); 5. lost to follow-up or withdrawn consent.
Query!
Timepoint [1]
0
0
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [1]
0
0
Overall Response (OR) as Assessed by the Independent Review Committee (PA DCO Only)
Query!
Assessment method [1]
0
0
Overall response rate was defined as the percentage of participants in each treatment group who achieve partial response (PR) or better per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) as their best response.
Complete Response (CR): No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.
Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or = 90% reduction in serum M-component with urine M-component \<100 mg/24 hours.
Partial Response (PR): = 50% reduction of serum M-protein and reduction in urine M-protein by = 90% or to \< 200 mg/24 hours. A = 50% reduction in the size of soft tissue plasmacytomas if present at baseline.
95% CIs for proportions were estimated using the Clopper-Pearson method.
Query!
Timepoint [1]
0
0
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [2]
0
0
Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee
Query!
Assessment method [2]
0
0
MRD\[-\]CR at 12 months was defined as achievement of CR per IMWG-URC by IRC and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (8 to 13 month window).
Query!
Timepoint [2]
0
0
12 Months (8- to 13-month window)
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
Overall survival was defined as the time from randomization until death from any cause. Deaths collected via public source, after end of study were included. Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive were censored at the date last known to be alive.
Query!
Timepoint [3]
0
0
Up to 58 months after the first participant was enrolled (at FA DCO, a median of 40.29 weeks of treatment [any study drug] in the Kd group and 79.29 weeks of treatment [any study drug] in the KdD group; FA DCO was 15 Apr 2022)
Query!
Secondary outcome [4]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Query!
Assessment method [4]
0
0
Treatment-emergent adverse events are defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier.
The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.
Treatment-related adverse events are treatment-emergent adverse events considered related to at least one study drug by the investigator, including those with unknown relationship.
Query!
Timepoint [4]
0
0
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Query!
Secondary outcome [5]
0
0
Kaplan-Meier Estimate for Duration of Response (DOR) (PA DCO Only)
Query!
Assessment method [5]
0
0
Duration of response (DOR) was defined as the time (in months) from first evidence of partial response (PR) or better per IMWG-URC by IRC to the earlier of disease progression or death due to any cause for participants with a best response of PR or better. For those who are alive and have not experienced disease progression at the time of data cutoff for analysis, duration of response was right-censored.
Medians were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Query!
Timepoint [5]
0
0
From Day 1 until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [6]
0
0
Kaplan-Meier Estimate for Time to Next Treatment (TTNT)
Query!
Assessment method [6]
0
0
Time to next treatment was defined as the time (in months) from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma. Time to next treatment for participants who do not start the subsequent treatment for multiple myeloma was censored at the date when the participant's information was last available.
Medians of TTNT duration were estimated using the Kaplan-Meier method. 95% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Query!
Timepoint [6]
0
0
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Query!
Secondary outcome [7]
0
0
Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (PA DCO Only)
Query!
Assessment method [7]
0
0
Time to progression was defined as the time (in months) from randomization to documented disease progression. Participants who did not have documented disease progression were censored at the date when data was last available.
Query!
Timepoint [7]
0
0
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [8]
0
0
Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)
Query!
Assessment method [8]
0
0
Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis.
95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.
Query!
Timepoint [8]
0
0
Randomization to Months 3, 6, 12, and 18
Query!
Secondary outcome [9]
0
0
Time to Overall Response as Assessed by the Independent Review Committee (PA DCO Only)
Query!
Assessment method [9]
0
0
Time to overall response was defined as the time from randomization to the earliest date a response of partial response (PR) or better as per IMWG-URC is first achieved and subsequently confirmed for participants with a best response of PR or better.
Query!
Timepoint [9]
0
0
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [10]
0
0
Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More
Query!
Assessment method [10]
0
0
A measure of the persistence of the CR (includes strict CR) per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) for 12 months or more after achieving MRD\[-\]CR status.
95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
Query!
Timepoint [10]
0
0
PA DCO: the longest treatment duration as of the PA DCO was 102.3 weeks; FA DCO: the longest treatment duration as of the FA DCO was 236.3 weeks
Query!
Secondary outcome [11]
0
0
Percentage of Participants With a Complete Response (CR) as Assessed by the Independent Review Committee (PA DCO Only)
Query!
Assessment method [11]
0
0
The percentage of participants in each treatment group who achieved stringent complete response (sCR) or CR per IMWG-URC, as assessed by the IRC, as their best response is presented.
Query!
Timepoint [11]
0
0
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Query!
Secondary outcome [12]
0
0
Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months
Query!
Assessment method [12]
0
0
MRD\[-\] at 12-month was defined as achievement of MRD\[-\] status as assessed by next-generation sequencing (NGS; at a 10\^-5 level) at the 12 months landmark (from 8 months to 13 months window).
95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.
Query!
Timepoint [12]
0
0
12 Months (8- to 13-month window)
Query!
Secondary outcome [13]
0
0
Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose
Query!
Assessment method [13]
0
0
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.
QLQ-C30 questionnaire was administered prior to dosing every 28 ± 7 days starting from cycle 1 day 1 through first follow-up visit (30 days \[+3\] after last dose of all study drugs).
Query!
Timepoint [13]
0
0
Baseline (Day 1 pre-dose) up to 236.3 weeks (longest treatment duration as of the FA DCO)
Query!
Eligibility
Key inclusion criteria
* Criteria 1 Relapsed or progressive multiple myeloma after last treatment
* Criteria 2 Males or females = 18 years of age
* Criteria 3 Measurable disease with at least 1 of the following assessed within 21 days prior to randomization:
* IgG multiple myeloma: serum monoclonal paraprotein (M-protein) level = 1.0 g/dL,
* IgA, IgD, IgE multiple myeloma: serum M-protein level = 0.5 g/dL,
* urine M-protein = 200 mg/24 hours,
* in subjects without measurable serum or urine M- protein, serum free light chain (SFLC) = 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
* Criteria 4 Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy
* Criteria 5 Prior therapy with carfilzomib is allowed as long as the patient had at least a partial response (PR) to most recent therapy with carfilzomib, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and will have at least a 6-month carfilzomib treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not proteasome inhibitors or CD38 antibodies during this 6-month carfilzomib treatment free interval)
* Criteria 6 Prior therapy with anti-CD38 antibodies is allowed as long as the patient had at least a PR to most recent therapy with CD38 antibody, was not removed due to toxicity, did not relapse within 60 days from intensive treatment (at least every other week) of CD38 antibody therapy, and will have at least a 6 month CD38 antibody treatment-free interval from last dose received until first study treatment
* Other inclusion criteria may apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Criteria 1 Waldenström macroglobulinemia
* Criteria 2 Multiple myeloma of IgM subtype
* Criteria 3 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
* Criteria 4 Plasma cell leukemia (> 2.0 * 10^9/L circulating plasma cells by standard differential)
* Criteria 5 Myelodysplastic syndrome
* Criteria 6 Known moderate or severe persistent asthma within the past 2 years
* Criteria 7 Known chronic obstructive pulmonary disease (COPD) with a FEV1 < 50% of predicted normal
* Criteria 8 Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, screening ECG with corrected QT interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization
* Other exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/06/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/04/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
466
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [2]
0
0
St Vincents Hospital Sydney - St Leonards
Query!
Recruitment hospital [3]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Royal Brisbane and Womens Hospital - Herston
Query!
Recruitment hospital [5]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [6]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [7]
0
0
Epworth Healthcare - East Melbourne
Query!
Recruitment hospital [8]
0
0
St Vincents Hospital Melbourne - Fitzroy, VIC
Query!
Recruitment hospital [9]
0
0
Barwon Health, University Hospital Geelong - Geelong
Query!
Recruitment hospital [10]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [5]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [8]
0
0
3065 - Fitzroy, VIC
Query!
Recruitment postcode(s) [9]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [10]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Mississippi
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Jersey
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
Austria
Query!
State/province [12]
0
0
Graz
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Salzburg
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Antwerpen
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Brussel
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Charleroi
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Gent
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Leuven
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Plovdiv
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Sofia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Alberta
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Ontario
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Brno
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Hradec Kralove
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Ostrava-Poruba
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Plzen
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Praha 2
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
La Roche Sur Yon Cedex 9
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Le Chesnay cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Lille Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Nantes Cedex 1
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Pessac Cedex
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Pierre-Benite cedex
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Poitiers Cedex
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Vandoeuvre les Nancy Cedex
Query!
Country [37]
0
0
Greece
Query!
State/province [37]
0
0
Athens
Query!
Country [38]
0
0
Greece
Query!
State/province [38]
0
0
Patra
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Thessaloniki
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Bekescsaba
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Budapest
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Debrecen
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szeged
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Aichi
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Chiba
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Fukuoka
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Gifu
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Gunma
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kyoto
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Niigata
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Okayama
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Osaka
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Saitama
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Tochigi
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Tokushima
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tokyo
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Goyang-si, Gyeonggi-do
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Hwasun, Jeollanam-do
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Bialystok
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Chorzow
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Lublin
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Poznan
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Warszawa
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Wroclaw
Query!
Country [66]
0
0
Romania
Query!
State/province [66]
0
0
Brasov
Query!
Country [67]
0
0
Romania
Query!
State/province [67]
0
0
Bucharest
Query!
Country [68]
0
0
Romania
Query!
State/province [68]
0
0
Bucuresti
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Cluj-Napoca
Query!
Country [70]
0
0
Romania
Query!
State/province [70]
0
0
Craiova
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Nizhny Novgorod
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Petrozavodsk
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Samara
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Saratov
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Castilla León
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Cataluña
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Navarra
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Madrid
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Taipei
Query!
Country [80]
0
0
Turkey
Query!
State/province [80]
0
0
Ankara
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Izmir
Query!
Country [82]
0
0
Turkey
Query!
State/province [82]
0
0
Samsun
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Leeds
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
London
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03158688
Query!
Trial related presentations / publications
Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, Usmani SZ, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28. No abstract available. Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2021 Dec;62(12):3002-3010. doi: 10.1080/10428194.2021.1941927. Epub 2021 Jun 26. Suzuki K, Min CK, Kim K, Lee JJ, Shibayama H, Ko PS, Huang SY, Li SS, Ding B, Khurana M, Iida S. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. Int J Hematol. 2021 Dec;114(6):653-663. doi: 10.1007/s12185-021-03204-9. Epub 2021 Aug 19. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, Usmani SZ. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022 Sep;198(6):988-993. doi: 10.1111/bjh.18233. Epub 2022 May 24. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. Erratum In: Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31669-X. Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 Feb;62(2):358-367. doi: 10.1080/10428194.2020.1832672. Epub 2020 Oct 28. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Shu X, Li C, Dimopoulos M. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023 Jul 25;7(14):3739-3748. doi: 10.1182/bloodadvances.2023010026.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Query!
Available to whom?
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.amgen.com/datasharing
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/88/NCT03158688/Prot_002.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/88/NCT03158688/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03158688